Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 9/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL844001 | 1.00 | CHRNA7 (0.58) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL843714 | 0.94 | CHRNA7 (0.62) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL843715 | 0.94 | CHRNA7 (0.62) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL842426 | 0.86 | CHRNA7 (0.61) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL842425 | 0.86 | CHRNA7 (0.61) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL843702 | 0.86 | CHRNA7 (0.61) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6008630 | 0.85 | CHRNA7 (0.56) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL843224 | 0.81 | CHRNA7 (0.62) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL843225 | 0.81 | CHRNA7 (0.62) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL843750 | 0.81 | CHRNA7 (0.59) | CHRNA7HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432707-B1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN CO LLC (US) | 2012-03-28 | — | — | EP | claimed |
| US-20050222196-A1 | Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease | PFIZER INC. | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222196-A1 | Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease | UGT2B7, CYP3A7, UGT1A7 | CHRNA7 5/4885HTR3E 1519/4885HTR3B 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.